Exelixis Inc
EXEL38.215USD
+0.785+2.10%
Market hours （ET）Quotes delayed by 15 min
10.77BMarket Cap
20.65P/E TTM
More Details of Exelixis Inc Company
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
Company codeEXEL
Company nameExelixis Inc
IPO dateApr 11, 2000
Founded at1994
CEODr. Michael M. Morrissey, Ph.D.
Number of employees1147
Security typeOrdinary Share
Fiscal year-endApr 11
Address1851 Harbor Bay Parkway
CityALAMEDA
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94502
Phone16508377000
Websitehttps://www.exelixis.com/
Company codeEXEL
IPO dateApr 11, 2000
Founded at1994
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Dr. Amy C. Peterson, M.D.
Dr. Amy C. Peterson, M.D.
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer
192.16K
+486.28%
Dr. George H. Poste, Ph.D.
Dr. George H. Poste, Ph.D.
Independent Director
Independent Director
150.18K
+1.27%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
72.17K
+2.67%
Ms. Julie Anne Smith
Ms. Julie Anne Smith
Independent Director
Independent Director
763.00
-92.92%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.37M
+33.08%
Dr. Stelios B. Papadopoulos, Ph.D.
Dr. Stelios B. Papadopoulos, Ph.D.
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
1.26M
+0.15%
Mr. Jeffrey J. Hessekiel, J.D.
Mr. Jeffrey J. Hessekiel, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
469.73K
+48.81%
Dr. Dana T. Aftab, Ph.D.
Dr. Dana T. Aftab, Ph.D.
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
Executive Vice President - Discovery and Translational Research, Chief Scientific Officer
391.52K
+51.34%
Mr. Patrick Joseph Haley
Mr. Patrick Joseph Haley
Executive Vice President - Commercial
Executive Vice President - Commercial
347.62K
+75.36%
Mr. Jack L. Wyszomierski
Mr. Jack L. Wyszomierski
Independent Director
Independent Director
337.77K
+2.73%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
By RegionUSD
Name
Revenue
Proportion
U.S
1.82B
84.06%
Europe
318.63M
14.69%
Japan
27.08M
1.25%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
CABOMETYX
1.80B
82.92%
License revenues
349.24M
16.10%
COMETRIQ
11.16M
0.51%
Collaboration services revenues
10.06M
0.46%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
10.66%
BlackRock Institutional Trust Company, N.A.
9.69%
Farallon Capital Management, L.L.C.
8.51%
Renaissance Technologies LLC
5.55%
State Street Global Advisors (US)
4.14%
Other
61.45%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
35.97%
Investment Advisor
33.06%
Hedge Fund
18.79%
Pension Fund
2.95%
Individual Investor
2.28%
Research Firm
1.77%
Sovereign Wealth Fund
1.22%
Bank and Trust
0.48%
Family Office
0.10%
Other
3.38%
Institutional Shareholding
Update time: Mon, Jan 20
Update time: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
972
265.48M
94.85%
-6.82M
2024Q4
992
262.76M
93.66%
-11.36M
2024Q3
924
259.58M
90.96%
-10.18M
2024Q2
908
255.61M
87.75%
-22.29M
2024Q1
905
264.69M
87.26%
-20.82M
2023Q4
882
270.85M
87.07%
-16.64M
2023Q3
847
278.02M
87.32%
-18.15M
2023Q2
833
285.95M
87.85%
-21.34M
2023Q1
841
294.75M
90.97%
-14.08M
2022Q4
839
295.50M
91.62%
-5.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
29.37M
10.49%
+120.47K
+0.41%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
26.71M
9.54%
-308.83K
-1.14%
Dec 31, 2024
Farallon Capital Management, L.L.C.
23.44M
8.37%
--
--
Mar 05, 2025
Renaissance Technologies LLC
15.30M
5.47%
-64.05K
-0.42%
Dec 31, 2024
State Street Global Advisors (US)
11.41M
4.08%
-31.73K
-0.28%
Dec 31, 2024
LSV Asset Management
8.17M
2.92%
+67.47K
+0.83%
Dec 31, 2024
Fuller & Thaler Asset Management Inc.
7.63M
2.73%
+708.31K
+10.23%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.16M
1.84%
-5.12K
-0.10%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
5.10M
1.82%
-153.57K
-2.92%
Dec 31, 2024
AQR Capital Management, LLC
3.97M
1.42%
+810.86K
+25.69%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
4.81%
Tema Oncology ETF
4.2%
Alger Russell Innovation ETF
3.77%
First Trust NYSE Arca Biotechnology Index Fund
3.34%
Burney US Factor Rotation ETF
3.31%
Invesco Biotechnology & Genome ETF
2.89%
ERShares Entrepreneurs ETF
2.66%
First Trust Health Care Alphadex Fund
2.51%
Range Cancer Immunotherapy ETF
2.48%
Adaptiv Select ETF
2.04%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion4.81%
Tema Oncology ETF
Proportion4.2%
Alger Russell Innovation ETF
Proportion3.77%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.34%
Burney US Factor Rotation ETF
Proportion3.31%
Invesco Biotechnology & Genome ETF
Proportion2.89%
ERShares Entrepreneurs ETF
Proportion2.66%
First Trust Health Care Alphadex Fund
Proportion2.51%
Range Cancer Immunotherapy ETF
Proportion2.48%
Adaptiv Select ETF
Proportion2.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data